Finance

Beta
Lists
RLMD:NASDAQ
Relmada Therapeutics Inc
$6.51
-3.84%
(-0.26) 1D
$6.51
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLMD...
Open
$6.82
High
$6.92
Low
$6.50
Mkt. cap
683.84M
Avg. vol.
1.33M
Volume
1.83M
52-wk high
$8.00
52-wk low
$0.52
EPS
-$1.15
Beta
0.39
Shares outstanding
104.89M
No. of employees
17
Open
$6.82
High
$6.92
Low
$6.50
Mkt. cap
683.84M
Avg. vol.
1.33M
Volume
1.83M
52-wk high
$8.00
52-wk low
$0.52
EPS
-$1.15
Beta
0.39
Shares outstanding
104.89M
No. of employees
17
News stories
From sources across the web
About Relmada Therapeutics Inc
CEO-
Employees17
Founded2004
HeadquartersCoral Gables, Florida, United States
SectorPharmaceutical industry
Websiterelmada.com
Analyst Ratings
Based on 3 analysts giving stock ratings to RLMD in the past 3 months
Strong Buy
Buy
3
Hold
0
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RLMD in the last 3 months.
Highest
Current $6.51
$19.00 (+191.86%)
Average
$14.33 (+120.12%)
Lowest
$12.00 (+84.33%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$12.00
+84.3%
06/23/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$12.00
+84.3%
05/13/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$19.00
+191.9%
05/14/2026
Christopher Liu
Lucid Capital
Buy
Initiated
$14.00
+115.1%
03/02/2026
Last report
Nov 10, 2022
Fiscal period
Q3 2022
EPS / Est. (USD)
-$1.31 / -$1.47
+10.88%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2022 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.82M
4.04M
5.17M
8.09M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.40M
6.29M
12.26M
11.37M
Operating expense
10.22M
10.33M
17.43M
19.46M
Total operating expenses
10.22M
10.33M
17.43M
19.46M
Operating income
-10.22M
-10.33M
-17.43M
-19.46M
Other non operating income
-
-
-
-
EBT including unusual items
-9.87M
-10.09M
-19.87M
-19.05M
EBT excluding unusual items
-9.90M
-10.08M
-17.05M
-18.50M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.87M
-10.09M
-19.87M
-19.05M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
321.46K
247.01K
387.23K
959.76K
Interest expense
-
-
-
-
Net interest expenses
321.46K
247.01K
387.23K
959.76K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer